Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-28,300
Closed -$7.84M 34
2022
Q4
$7.84M Buy
28,300
+5,800
+26% +$1.64M 1.13% 25
2022
Q3
$6.01M Sell
22,500
-27,300
-55% -$5.8M 0.81% 30
2022
Q2
$10.2M Sell
49,800
-5,600
-10% -$1.14M 1.19% 14
2022
Q1
$11.7M Sell
55,400
-25,700
-32% -$5.59M 0.33% 68
2021
Q4
$19.5M Sell
81,100
-14,900
-16% -$3.83M 0.4% 41
2021
Q3
$27.2M Sell
96,000
-82,400
-46% -$27M 0.82% 15
2021
Q2
$61.8M Sell
178,400
-114,900
-39% -$34.8M 2.19% 2
2021
Q1
$82.1M Buy
293,300
+201,500
+219% +$54.3M 2.05% 3
2020
Q4
$22.5M Buy
91,800
+35,100
+62% +$9.05M 0.43% 41
2020
Q3
$16.1M Buy
+56,700
New +$15.8M 0.59% 33
2020
Q1
Sell
-15,000
Closed -$4.45M 359
2019
Q4
$4.45M Buy
+15,000
New +$4.16M 0.28% 32
2018
Q1
Sell
-6,800
Closed -$2.17M 91
2017
Q4
$2.17M Buy
+6,800
New +$2.18M 0.71% 29
2017
Q1
Sell
-42,000
Closed -$11M 228
2016
Q4
$11M Buy
+42,000
New +$12.4M 1.77% 15

Other funds holding BIIB

SG3 Management's BIIB Position: Q2 2022 in Review

SG3 Management sold out of Biogen (BIIB) in Q2 2022, closing a stake of 15,000 shares — an estimated $3.07M sold.

SG3 Management first reported a position in BIIB in Q4 2020 and held it in 5 quarters. The position peaked at $8.77M in Q1 2021. 928 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

  • SG3 Management reported no remaining Biogen position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 15,000 Biogen shares in Q2 2022, an estimated $3.07M.
  • SG3 Management first reported a position in Biogen in Q4 2020 and held it in 5 quarters.
  • SG3 Management's Biogen position peaked at $8.77M in Q1 2021.
  • 928 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.